Add BrightSurf on Google Email

Science News for June 4, 2023


Association of immunotherapy duration with overall survival in advanced non–small cell lung cancer – this study is being released to coincide with a poster presentation at the 2023 ASCO annual meeting

A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.

SourceJAMA Network·JournalJAMA Oncology·DateJun 4, 2023

Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer

A retrospective cohort study suggests that stopping immunotherapy treatment at two years is a valid strategy without compromising overall survival. The researchers analyzed data from 1,091 patients and found similar overall survival probabilities between those who stopped treatment and continued it indefinitely.

Researchers from Tel Aviv University and UCLA developed a method of deep-brain stimulation during sleep to improve memory consolidation

Researchers from Tel Aviv University and UCLA developed a method to improve memory consolidation by inducing deep-brain stimulation during sleep. The study found that precise timing of electrical stimulation enhances synchronization between the hippocampus and frontal cortex, leading to improved accuracy in recalling memories.

SourceTel-Aviv University·JournalNature Neuroscience·DateJun 4, 2023

Clinical trial points to treatment advances for glioma patients for first time in decades

A phase 3 clinical trial by Dana-Farber Cancer Institute has shown vorasidenib significantly prolongs progression-free survival and delays radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma. Treatment with vorasidenib can delay cognitive dysfunction in patients and preserve their quality of life.

SourceDana-Farber Cancer Institute·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJun 4, 2023

Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

The Phase 3 S1826 trial demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma treated with nivolumab and chemotherapy. The therapy was well-tolerated, with few serious immune-related side effects.

SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateJun 4, 2023

Whales not to be counted on as ‘climate savers’: study

A recent study led by Griffith University found that whales do not significantly contribute to the removal of atmospheric carbon, contrary to previous hopes. The research suggests that other methods, such as protecting marine environments and natural carbon capture, are more effective in reducing greenhouse gases.

SourceGriffith University·JournalFrontiers in Marine Science·TypeComputational simulation/modeling·DateJun 4, 2023